Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
Winter Storm Disrupts Northeast Travel as Snow and Ice Blanket New York, New Jersey 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
DUBLIN, Ireland, Feb. 14, 2017 -- Horizon Pharma plc (Nasdaq:HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, announced today that the company will present at the Cowen and Company 37th Annual Health Care Conference at 2:40 p.m. ET on March 6, 2017 in Boston, MA.
The conference presentation will be webcast live and may be accessed by visiting Horizon's investor relations section of the website at http://ir.horizon-pharma.com. A replay of the webcast will be available for the event.
About Horizon Pharma plc
Horizon Pharma plc is a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. The Company markets 11 medicines through its orphan, rheumatology and primary care business units. For more information, please visit www.horizonpharma.com. Follow @HZNPplc on Twitter or view careers on our LinkedIn page.
Contacts: Tina Ventura Senior Vice President, Investor Relations [email protected] U.S. Media: Geoff Curtis Senior Vice President, Corporate Communications [email protected] Ireland Media: Ray Gordon Gordon MRM [email protected]
